Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from MedAdvisor Limited ( (AU:AHE) ) is now available.
MedAdvisor subsidiary Adheris Health has disclosed a substantial on-market share purchase by director Lucas Merrow, signalling increased insider confidence in the company. Merrow acquired 890,000 fully paid ordinary shares on 3 March 2026 at an average price of $0.022 per share, lifting his direct holding to 2,330,290 shares while retaining 1,250,000 unlisted options expiring at the end of 2031.
The transaction, which did not occur during a closed trading period, indicates a material increase in the director’s equity exposure and aligns his interests more closely with other shareholders. The company emphasised that the change solely reflects on-market trades and does not involve any new contracts or derivative arrangements relating to Merrow’s interests.
The most recent analyst rating on (AU:AHE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:AHE Stock Forecast page.
More about MedAdvisor Limited
Adheris Health Limited, now part of MedAdvisor Limited, operates in the health technology and medication adherence sector. The company focuses on digital and data-driven services that support patients in managing prescriptions and adherence programs, working with pharmacies, healthcare providers and life sciences partners to improve health outcomes and engagement.
Average Trading Volume: 568,355
Technical Sentiment Signal: Sell
Current Market Cap: A$14.01M
For detailed information about AHE stock, go to TipRanks’ Stock Analysis page.